Aug. 8, 2025 - Epoch Times
01:43
| 
| Time | Text |
|---|---|
| So it sounds like you're saying that the benefits are oversold and the risks are undersold as a general. | |
| I think that's a pretty great way to sum that up. | |
| And the data supports that. | |
| When these medications first came to market, Dr. Daniel E. Casey, a psychiatrist of the Portland VA at that time, he was also the chair of the FDA's Psychopharmacological Drug Advisory Committee. | |
| And in these hearings, the entire debate was about efficacy. | |
| The drug companies were required to submit two studies to the FDA for review. | |
| They could have done twenty others, but they just needed to show two that showed some level of efficacy. | |
| When you read these entire transcripts which I've done, the entire debate for these multi hour meetings, hearings, were solely about efficacy, and we have a belief that we can trust our government. | |
| We believe that these medications are studied rigorously, that we are looking for not just efficacy but safety, but what we now know is that that has not been happening, and it never was. | |
| And now we have a suicide epidemic, not just of veterans, but of the entire American population. | |
| Suicide rates have continued to skyrocket for all groups. | |
| Young women from 20 to 21, prescription rates of antidepressants went up by 130%. | |
| For young women to age 24, went up by 60%. | |
| And during that period, suicides of those groups spiked. | |
| For young men, prescription rates stayed the same or declined slightly, and we did not see the suicide spikes that we did with young boys and young men. |
Export Selection